New in Immunology

Read more


Our new Primary Immunodeficiency (PID) and Primary Ciliary Dyskinesia (PCD) Panel consists of 308 carefully curated genes.


The Choice is Yours

Read more


Over 220 panels to choose from, with the ability to customize by adding or removing genes.


Easy ordering and networking platform for clinicians

Read more about Nucleus

“The genetic services of Blueprint Genetics were highly professional. Their results came in due time, together with a thorough and insightful interpretation, reflecting high professional standards. We were very pleased with this collaboration and wish to continue it.”

Dr. R.Jurcut cardiologist, cardiomyopathy expert


New in Immunology: Primary Immunodeficiency / Primary Ciliary Dyskinesia Panel

Published on June 12, 2018

The aim of the new panel is to increase the clinical utility and diagnostic yield for patients with a clinical suspicion of primary immunodeficiency (PID), especially for those patients where primary ciliary dyskinesia (PCD) is included in the differential diagnosis. In these cases, the core symptoms are often very similar…

Read more

See all news


Nordic Congress of Ophthalmology

Oslo 22-25 August 2018

Oslo Kongressenter Folkets Hus AS, Youngs gate, Oslo, Norway

We will be attending Nordic Congress of Ophthalmology in Oslo. This event offers a comprehensive scientific program with 140 speakers, exhibitors and top international contributors from all Nordic countries. We invite you to visit us at our booth and hear more about Blueprint Genetics’s diagnostic tests for patients…

Read more

See all events


Blueprint Genetics is a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory. Our Sequence Analysis is ISO 15189  accredited in every step from sample arrival to clinical interpretation. The ISO 15189 standard accreditation is carried by FINAS and the information about the scope is available on the website www.finas.fi/Documents/T292_A01_2016.pdf.   Read more

Get our latest updates directly to your mailbox.